Jeil Pharmaceutical KRX:271980KOSPI
제일약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Jeil Pharmaceutical reported revenue of ₩147bn, up 6.5% year on year, and an operating loss of ₩7.0bn. Jeil Pharmaceutical (제일약품) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 1 article.
Jeil Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩147bn | +6.5% | −₩7.0bn | −₩6.7bn |
| Q1 2026 | ₩130bn | -20.1% | ₩418m | ₩3.2bn |
| Q4 2025 derived | ₩132bn | -29.3% | ₩534m | ₩9.5bn |
| Q3 2025 | ₩135bn | -22.7% | ₩9.8bn | ₩15.9bn |
| Q2 2025 | ₩138bn | -20.5% | ₩4.7bn | ₩3.0bn |
| Q1 2025 | ₩163bn | -4.3% | ₩5.7bn | ₩3.6bn |
| Q4 2024 derived | ₩187bn | +3.8% | ₩2.4bn | ₩6.2bn |
| Q3 2024 | ₩174bn | -1.6% | −₩4.1bn | −₩5.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Jeil Pharmaceutical top stories 2 weeks, by number of outlets
- 1